PGR and breast carcinoma: The current standard of care requires all newly diagnosed cases of invasive breast cancer to be routinely tested by immunohistochemistry (IHC) for the expression of estrogen receptor alpha (ER), progesterone receptor (PR) and the growth factor receptor HER2/neu (ERBB2).